Sienna Biopharmaceuticals is a clinical-stage biopharmaceutical company. Co.'s primary product candidates from its technological platform are SNA-120 (pegcantratinib), a first-in-class TrkA inhibitor for the topical treatment of psoriasis, as well as the associated pruritus; and SNA-125, a topical JAK3/TrkA inhibitor with the potential to treat various inflammatory conditions, including atopic dermatitis, psoriasis and the associated pruritus. Co.'s second technology platform, Topical Photoparticle Therapy, utilizes silver particles applied to the skin to direct the light from commercially available lasers to the hair follicle or sebaceous gland to cause selective photothermolysis. The SNNA average annual return since 2017 is shown above.
The Average Annual Return on the SNNA average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SNNA average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SNNA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|